Reports Q3 revenue $118.7M, consensus $115.22M. “Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we’re having on patients,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “We’ve established a new category in eye care, and XDEMVY is now one of the best-selling prescription eye drops. Simultaneously, we are expanding our pipeline with more category-creating programs like ocular rosacea – another widespread condition with significant unmet need – that position Tarsus for sustained, long-term growth. With each new milestone, we are deepening our impact and shaping the future of eye care.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- TARS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Promising Growth and Market Penetration of XDEMVY Drives Buy Rating and Increased Price Target
- Tarsus Pharmaceuticals price target raised to $88 from $72 at H.C. Wainwright
- Tarsus Pharmaceuticals price target raised to $85 from $80 at BofA